Sign in

Ikenna Onwe

Research Analyst at TD Cowen

Ikenna Onwe is an equity research analyst at TD Cowen, but based on available public sources, specific details about his full title, sector specialization, company coverage, performance metrics, and career timeline are not immediately accessible. There is no substantiated record of coverage universes, success rates, or third-party analyst rankings tied to his name. Additionally, prior career history, credential verification, and notable recognitions are not found in the current search results. Professional credentials and regulatory registrations could not be verified without direct access to his FINRA profile or more comprehensive industry databases.

Ikenna Onwe's questions to Arcutis Biotherapeutics (ARQT) leadership

Ikenna Onwe's questions to Arcutis Biotherapeutics (ARQT) leadership • Q2 2025

Question

Ikenna Onwe, on behalf of Tyler Van Buren at TD Cowen, asked for an update on the COVA partnership's contribution to growth and the early utilization trends of the newly established national dedicated pharmacy for the primary care channel.

Answer

Chief Commercial Officer Todd Edwards explained that adoption in the primary care market is proceeding at a slower pace as anticipated, due to longer selling cycles and lower familiarity with non-steroidal topicals. He confirmed that COVA is executing well and that the new national pharmacy is showing positive early signals by streamlining the prescribing and fulfillment process for primary care physicians, which is a critical step for driving adoption in that channel.

Ask Fintool Equity Research AI